Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: james who wrote (1355)	12/3/1997 10:03:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 4676

James: >> So can a mutated hTR compete with native hTR for the assembly & inactivate the enzyme? Is this one of the things Geron is trying?<< Several RNA modification can give telomerase inhibition (by competition with native one). Some of them: 1. hTR (RNA component of the telomerase) have multiple telomere unit sequence (translation part) and this part will have to be removed or sequence altered, 2. Binding hTR/hTRT site nucleotide sequence can be altered-loss of binding, and 3. Altering RNO sequence for catalytic subunit mRNA . Is this gene manipulation for specific site/target possible without effecting healthy gene, I do not know. >> Many biologists I know of have high regards of Dr.Y<< Believe me, so do I. RE SUGN: I guess prostate P I/II data was surprise for SUGN. mz